When urothelial differentiation pathways go wrong: Implications for bladder cancer development and progression

Urologic Oncology: Seminars and Original Investigations

Volumn 31, Issue 6, 2013, Pages 802-811

  DeGraff, David J ^a   Cates, Justin M ^a   Mauney, Joshua R ^b   Clark, Peter E ^a   Matusik, Robert J ^a   Adam, Rosalyn M ^b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Bladder cancer; Differentiation; FOXA1; PPAR ; Retinoic acid; Transcription factors

Indexed keywords

CYTOKERATIN 20; HEPATOCYTE NUCLEAR FACTOR 3ALPHA; HERMES ANTIGEN; INTERFERON REGULATORY FACTOR 1; KERATINOCYTE GROWTH FACTOR; KRUPPEL LIKE FACTOR 4; MESSENGER RNA; OCTAMER TRANSCRIPTION FACTOR 4; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P53; PROTEIN P63; PROTEIN P73; RETINOIC ACID; RETINOIC ACID RECEPTOR BETA; RETINOID; TRANSCRIPTION FACTOR GATA 4; TRANSCRIPTION FACTOR GATA 6; TUMOR MARKER; UROPLAKIN; VASCULOTROPIN RECEPTOR;

BLADDER CANCER; CANCER GROWTH; CANCER PROGNOSIS; CELL DIFFERENTIATION; DOWN REGULATION; HISTOPATHOLOGY; HUMAN; MESENCHYME; METASTASIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSITIONAL CELL CARCINOMA; UPREGULATION; UROTHELIUM;

BLADDER CANCER; DIFFERENTIATION; FOXA1; PPARΓ; RETINOIC ACID; TRANSCRIPTION FACTORS;

CARCINOMA; CELL DIFFERENTIATION; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPATOCYTE NUCLEAR FACTOR 3-ALPHA; HUMANS; MUSCLES; NEOPLASM METASTASIS; NEOPLASM STAGING; PPAR GAMMA; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TRETINOIN; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 84880696798     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2011.07.017     Document Type: Review

References (111)

1. Cordon-Cardo C., Cote R.J., Sauter G. Genetic and molecular markers of urothelial premalignancy and malignancy. Scand J Urol Nephrol 2000, (Suppl): 82-93.
2. Castillo-Martin M., Domingo-Domenech J., Karni-Schmidt O., et al. Molecular pathways of urothelial development and bladder tumorigenesis. Urol Oncol 2010, 28: 401-408.
3. Sun T.T., Zhao H., Provet J., et al. Formation of asymmetric unit membrane during urothelial differentiation. Mol Biol Rep 1996, 23: 3-11.
4. Wu X.R., Kong X.P., Pellicer A., et al. Uroplakins in urothelial biology, function, and disease. Kidney Int 2009, 75: 1153-1165.
5. Sun T.T., Liang F.X., Wu X.R. Uroplakins as markers of urothelial differentiation. Adv Exp Med Biol 1999, 462: 7-18.
6. Wu X.R., Lin J.H., Walz T., et al. Mammalian uroplakins. A group of highly conserved urothelial differentiation-related membrane proteins. J Biol Chem 1994, 269: 13716-13724.
7. Epstein J.I., Amin M.B., Reuter V.R., et al. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol 1998, 22: 1435-1448.
8. Murphy W., Grignon D., Perlman E. Tumors of the Urinary Bladder. Atlas of Tumor Biology 2004, 241-361. AFIP, Washington, DC. S. Silverberg, L. Sobin (Eds.).
9. Hu P., Deng F.M., Liang F.X., et al. Ablation of uroplakin III gene results in small urothelial plaques, urothelial leakage, and vesico-ureteral reflux. J Cell Biol 2000, 151: 961-972.
10. Hu P., Meyers S., Liang F.X., et al. Role of membrane proteins in permeability barrier function: Uroplakin ablation elevates urothelial permeability. Am J Physiol Renal Physiol 2002, 283: F1200-F1207.
11. Signoretti S., Pires M.M., Lindauer M., et al. p63 Regulates commitment to the prostate cell lineage. Proc Natl Acad Sci U S A 2005, 102: 11355-11360.
12. Karni-Schmidt O., Castillo-Martin M., HuaiShen T., et al. Distinct expression profiles of p63 variants during urothelial development and bladder cancer progression. Am J Pathol 2011, 178: 1350-1360.
13. Hanahan D., Weinberg R.A. Hallmarks of cancer. The next generation. Cell 2011, 144: 646-674.
14. Li Y., Liu W., Hayward S.W., et al. Plasticity of the urothelial phenotype: Effects of gastro-intestinal mesenchyme/stroma and implications for urinary tract reconstruction. Differentiation 2000, 66: 126-135.
15. Higuchi T.T., Granberg C.F., Fox J.A., et al. Augmentation cystoplasty and risk of neoplasia: Fact, fiction, and controversy. J Urol 2010, 184: 2492-2496.
16. Soergel T.M., Cain M.P., Misseri R., et al. Transitional cell carcinoma of the bladder following augmentation cystoplasty for the neuropathic bladder. J Urol 2004, 172: 1649-1651.
17. Droller M.J. Biological considerations in the assessment of urothelial cancer: A retrospective. Urology 2005, 66: 66-75.
18. Goebell P.J., Knowles M.A. Bladder cancer or bladder cancers?. Genetically distinct malignant conditions of the urothelium. Urol Oncol 2010, 28: 409-428.
19. Aboseif S., El-Sakka A., Young P., et al. Mesenchymal reprogramming of adult human epithelial differentiation. Differentiation 1999, 65: 113-118.
20. Cunha G.R., Chung L.W., Shannon J.M., et al. Hormone-induced morphogenesis and growth: Role of mesenchymal-epithelial interactions. Recent Prog Horm Res 1983, 39: 559-598.
21. DiSandro M.J., Li Y., Baskin L.S., et al. Mesenchymal-epithelial interactions in bladder smooth muscle development: Epithelial specificity. J Urol 1998, 160: 1040-1046.
22. Donjacour A.A., Cunha G.R. Induction of prostatic morphology and secretion in urothelium by seminal vesicle mesenchyme. Development 1995, 121: 2199-2207.
23. Neubauer B.L., Chung L.W., McCormick K.A., et al. Epithelial-mesenchymal interactions in prostatic development. II. Biochemical observations of prostatic induction by urogenital sinus mesenchyme in epithelium of the adult rodent urinary bladder. J Cell Biol 1983, 96: 1671-1676.
24. Baskin L.S., Sutherland R.S., Thomson A.A., et al. Growth factors and receptors in bladder development and obstruction. Lab Invest 1996, 75: 157-166.
25. Montironi R., Lopez-Beltran A., Scarpelli M., et al. Morphological classification and definition of benign, preneoplastic, and noninvasive neoplastic lesions of the urinary bladder. Histopathology 2008, 53: 621-633.
26. Reuter V. WHO noninvasive papillary urothelial carcinoma, high-grade. World Health Organization Classification of Tumors. Pathology and Genetic Tumors of the Urinary System 2004, 117-118. IARC Press, Lyon. J. Eble, G. Sauter, J. Epstein (Eds.).
27. Lopez-Beltran A., Sauter G., Gasser T., et al. Infiltrating Urothelial Carcinoma. World Health Organization Classification of Tumors. Pathology and Genetics of the Urinary System 2004, 93-109. IARC Press, Lyon. J. Eble, G. Sauter, J. Epstein (Eds.).
28. Sesterhen I. WHO Urothelial carcinoma in situ. World Health Organization Classification of Tumors 2004, 119-120. IARC Press, Lyon. J. Eble, G. Sauter, J. Epstein (Eds.).
29. Humphrey P.A. Urinary bladder pathology 2004: An update. Ann Diagn Pathol 2004, 8: 380-389.
30. van Rhijn B.W., Vis A.N., van der Kwast T.H., et al. Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome. J Clin Oncol 2003, 21: 1912-1921.
31. Simon R., Jones P., Sidransky D., et al. WHO Genetics and predictive factors of noninvasive urothelial neoplasias. World Health Organization Classification of Tumors. Pathology and Genetic Tumors of the Urinary System and Male Genital Organs 2004, 120-123. IARC Press, Lyon. J. Eble, G. Sauter, J. Epstein (Eds.).
32. Urist M.J., Di Como C.J., et al. Loss of p63 expression is associated with tumor progression in bladder cancer. Am J Pathol 2002, 161: 1199-1206.
33. McKenney J.K., Desai S., Cohen C., et al. Discriminatory immunohistochemical staining of urothelial carcinoma in situ and non-neoplastic urothelium: An analysis of cytokeratin 20, p53, and CD44 antigens. Am J Surg Pathol 2001, 25: 1074-1078.
34. Harnden P., Eardley I., Joyce A.D., et al. Cytokeratin 20 as an objective marker of urothelial dysplasia. Br J Urol 1996, 78: 870-875.
35. Desai S., Lim S.D., Jimenez R.E., et al. Relationship of cytokeratin 20 and CD44 protein expression with WHO/ISUP grade in pTa and pT1 papillary urothelial neoplasia. Mod Pathol 2000, 13: 1315-1323.
36. Rotterud R., Nesland J.M., Berner A., et al. Expression of the epidermal growth factor receptor family in normal and malignant urothelium. BJU Int 2005, 95: 1344-1350.
37. Amsellem-Ouazana D., Bieche I., Tozlu S., et al. Gene expression profiling of ERBB receptors and ligands in human transitional cell carcinoma of the bladder. J Urol 2006, 175: 1127-1132.
38. Thogersen V.B., Sorensen B.S., Poulsen S.S., et al. A subclass of HER1 ligands are prognostic markers for survival in bladder cancer patients. Cancer Res 2001, 61: 6227-6233.
39. Chow N.H., Chan S.H., Tzai T.S., et al. Expression profiles of ErbB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder. Clin Cancer Res 2001, 7: 1957-1962.
40. Nicholson R.I., Gee J.M., Harper M.E. EGFR and cancer prognosis. Eur J Cancer 2001, 37(Suppl 4): S9-S15.
41. Memon A.A., Sorensen B.S., Meldgaard P., et al. The relation between survival and expression of HER1 and HER2 depends on the expression of HER3 and HER4: A study in bladder cancer patients. Br J Cancer 2006, 94: 1703-1709.
42. Memon A.A., Sorensen B.S., Melgard P., et al. Expression of HER3, HER4, and their ligand heregulin-4 is associated with better survival in bladder cancer patients. Br J Cancer 2004, 91: 2034-2041.
43. Cheng J., Huang H., Zhang Z.T., et al. Overexpression of epidermal growth factor receptor in urothelium elicits urothelial hyperplasia and promotes bladder tumor growth. Cancer Res 2002, 62: 4157-4163.
44. Adam R.M., Danciu T., McLellan D.L., et al. A nuclear form of the heparin-binding epidermal growth factor-like growth factor precursor is a feature of aggressive transitional cell carcinoma. Cancer Res 2003, 63: 484-490.
45. Kramer C., Klasmeyer K., Bojar H., et al. Heparin-binding epidermal growth factor-like growth factor isoforms and epidermal growth factor receptor/ErbB1 expression in bladder cancer and their relation to clinical outcome. Cancer 2007, 109: 2016-2024.
46. Nanba D., Mammoto A., Hashimoto K., et al. Proteolytic release of the carboxy-terminal fragment of proHB-EGF causes nuclear export of PLZF. J Cell Biol 2003, 163: 489-502.
47. Toki F., Nanba D., Matsuura N., et al. Ectodomain shedding of membrane-anchored heparin-binding EGF like growth factor and subcellular localization of the C-terminal fragment in the cell cycle. J Cell Physiol 2005, 202: 839-848.
48. Kinugasa Y., Hieda M., Hori M., et al. The carboxyl-terminal fragment of pro-HB-EGF reverses Bcl6-mediated gene repression. J Biol Chem 2007, 282: 14797-14806.
49. Hirata Y., Ogasawara N., Sasaki M., et al. BCL6 degradation caused by the interaction with the C-terminus of pro-HB-EGF induces cyclin D2 expression in gastric cancers. Br J Cancer 2009, 100: 1320-1329.
50. Varley C.L., Stahlschmidt J., Lee W.C., et al. Role of PPARγ and EGFR signaling in the urothelial terminal differentiation program. J Cell Sci 2004, 117: 2029-2036.
51. Varley C.L., Garthwaite M.A., Cross W., et al. PPARγ-regulated tight junction development during human urothelial cytodifferentiation. J Cell Physiol 2006, 208: 407-417.
52. Balestreire E.M., Apodaca G. Apical epidermal growth factor receptor signaling: Regulation of stretch-dependent exocytosis in bladder umbrella cells. Mol Biol Cell 2007, 18: 1312-1323.
53. Baskin L.S., Hayward S.W., Sutherland R.A., et al. Cellular signaling in the bladder. Front Biosci 1997, 2: d592-d595.
54. van Rhijn B.W., Lurkin I., Radvanyi F., et al. The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. Cancer Res 2001, 61: 1265-1268.
55. van Rhijn B.W., Montironi R., Zwarthoff E.C., et al. Frequent FGFR3 mutations in urothelial papilloma. J Patho 2002, 198: 245-251.
56. Tash J.A., David S.G., Vaughan E.E., et al. Fibroblast growth factor-7 regulates stratification of the bladder urothelium. J Urol 2001, 166: 2536-2541.
57. Yi E.S., Shabaik A.S., Lacey D.L., et al. Keratinocyte growth factor causes proliferation of urothelium in vivo. J Urol 1995, 154: 1566-1570.
58. Baskin L.S., Sutherland R.S., Thomson A.A., et al. Growth factors in bladder wound healing. J Urol 1997, 157: 2388-2395.
59. Haraguchi R., Motoyama J., Sasaki H., et al. Molecular analysis of coordinated bladder and urogenital organ formation by Hedgehog signaling. Development 2007, 134: 525-533.
60. Tasian G., Cunha G., Baskin L. Smooth muscle differentiation and patterning in the urinary bladder. Differentiation 2010, 80: 106-117.
61. Chen M., Hildebrandt M.A., Clague J., et al. Genetic variations in the sonic hedgehog pathway affect clinical outcomes in non-muscle-invasive bladder cancer. Cancer Prev Res (Phila) 2010, 3: 1235-1245.
62. Chambon P. A decade of molecular biology of retinoic acid receptors. FASEB J 1996, 10: 940-954.
63. Ross S.A., McCaffery P.J., Drager U.C., et al. Retinoids in embryonal development. Physiol Rev 2000, 80: 1021-1054.
64. Wilson J.G., Warkany J. Malformations in the genitourinary tract induced by maternal vitamin A deficiency in the rat. Am J Anat 1948, 83: 357-407.
65. Batourina E., Tsai S., Lambert S., et al. Apoptosis induced by vitamin A signaling is crucial for connecting the ureters to the bladder. Nat Genet 2005, 37: 1082-1089.
66. Zou C., Liebert M., Zou C., et al. Identification of effective retinoids for inhibiting growth and inducing apoptosis in bladder cancer cells. J Urol 2001, 165: 986-992.
67. Boorjian S., Scherr D.S., Mongan N.P., et al. Retinoid receptor mRNA expression profiles in human bladder cancer specimens. Int J Oncol 2005, 26: 1041-1048.
68. Hurst R.E., Waliszewski P., Waliszewska M., et al. Complexity, retinoid-responsive gene networks, and bladder carcinogenesis. Adv Exp Med Biol 1999, 462: 449-467.
69. Molloy C.J., Laskin J.D. Effect of retinoid deficiency on keratin expression in mouse bladder. Exp Mol Pathol 1988, 49: 128-140.
70. Liang F.X., Bosland M.C., Huang H., et al. Cellular basis of urothelial squamous metaplasia: Roles of lineage heterogeneity and cell replacement. The J Cell Biol 2005, 171: 835-844.
71. Squire R.A., Sporn M.B., Brown C.C., et al. Histopathologic evaluation of the inhibition of rat bladder carcinogenesis by 13-cis-retinoic acid. Cancer Res 1977, 37: 2930-2936.
72. Grubbs C.J., Moon R.C., Squire R.A., et al. 13-cis-Retinoic acid: Inhibition of bladder carcinogenesis induced in rats by N-butyl-N-(4-hydroxybutyl)nitrosamine. Science 1977, 198: 743-744.
73. Zou C., Zhou J., Qian L., et al. Comparing the effect of ATRA, 4-HPR, and CD437 in bladder cancer cells. Front Biosci 2006, 11: 2007-2016.
74. Sabichi A.L., Lerner S.P., Atkinson E.N., et al. Phase III prevention trial of fenretinide in patients with resected non-muscle-invasive bladder cancer. Clin Cancer Res 2008, 14: 224-229.
75. Studer U.E., Jenzer S., Biedermann C., et al. Adjuvant treatment with a vitamin A analogue (etretinate) after transurethral resection of superficial bladder tumors. Final analysis of a prospective, randomized multicenter trial in Switzerland. Eur Urol 1995, 28: 284-290.
76. Mauney J.R., Ramachandran A., Yu R.N., et al. All-trans retinoic acid directs urothelial specification of murine embryonic stem cells via GATA4/6 signaling mechanisms. PLoS One 2010, 5: e11513.
77. Southgate J., Hutton K.A., Thomas D.F., et al. Normal human urothelial cells in vitro: Proliferation and induction of stratification. Lab Invest 1994, 71: 583-594.
78. Guan Y., Zhang Y., Davis L., et al. Expression of peroxisome proliferator-activated receptors in urinary tract of rabbits and humans. Am J Physiol 1997, 273: F1013-F1022.
79. Jain S., Pulikuri S., Zhu Y., et al. Differential expression of the peroxisome proliferator-activated receptor-γ (PPARγ) and its coactivators steroid receptor coactivator-1 and PPAR-binding protein PBP in the brown fat, urinary bladder, colon, and breast of the mouse. Am J Pathol 1998, 153: 349-354.
80. Kawakami S., Arai G., Hayashi T., et al. PPARγ ligands suppress proliferation of human urothelial basal cells in vitro. J Cell Physiol 2002, 191: 310-319.
81. Nakashiro K.I., Hayashi Y., Kita A., et al. Role of peroxisome proliferator-activated receptor-γ and its ligands in non-neoplastic and neoplastic human urothelial cells. Am J Pathol 2001, 159: 591-597.
82. Varley C.L., Stahlschmidt J., Smith B., et al. Activation of peroxisome proliferator-activated receptor-γ reverses squamous metaplasia and induces transitional differentiation in normal human urothelial cells. Am J Pathol 2004, 164: 1789-1798.
83. Blanquart C., Barbier O., Fruchart J.C., et al. Peroxisome proliferator-activated receptors: Regulation of transcriptional activities and roles in inflammation. J Steroid Biochem Mol Biol 2003, 85: 267-273.
84. Varley C.L., Bacon E.J., Holder J.C., et al. FoxA1 and IRF-1 intermediary transcriptional regulators of PPARγ-induced urothelial cytodifferentiation. Cell Death Differ 2009, 16: 103-114.
85. Oottamasathien S., Wang Y., Williams K., et al. Directed differentiation of embryonic stem cells into bladder tissue. Dev Biol. Cell Death Differ 2009, 16: 103-166.
86. Drori S., Girnun G.D., Tou L., et al. Hic-5 regulates an epithelial program mediated by PPARγ. Genes Dev. Cell Death Differ 2009, 16: 103-175.
87. Rageul J., Mottier S., Jarry A., et al. KLF4-dependent, PPARγ-induced expression of GPA33 in colon cancer cell lines. Int J Cancer 2009, 125: 2802-2809.
88. Ohnishi S., Ohnami S., Laub F., et al. Down-regulation and growth inhibitory effect of epithelial-type Kruppel-like transcription factor KLF4, but not KLF5, in bladder cancer. Biochem Biophys Res Commun 2003, 308: 251-256.
89. Chen X., Whitney E.M., Gao S.Y., et al. Transcriptional profiling of Kruppel-like factor 4 reveals a function in cell cycle regulation and epithelial differentiation. J Mol Biol 2003, 326: 665-677.
90. Hannenhalli S., Kaestner K.H. The evolution of Fox genes and their role in development and disease. Nat Rev Genet 2009, 10: 233-240.
91. Cirillo L.A., Lin F.R., Cuesta I., et al. Opening of compacted chromatin by early developmental transcription factors HNF3 (FoxA) and GATA-4. Mol Cell 2002, 9: 279-289.
92. Friedman J.R., Kaestner K.H. The FoxA family of transcription factors in development and metabolism. Cell Mol Life Sci 2006, 63: 2317-2328.
93. DeGraff D.J., Yu X., Sun Q., et al. The role of FoxA proteins in the regulation of androgen receptor activity. Androgen Action in Prostate Cancer 2008, Springer, New York. D.J. Tindall, J.L. Mohler (Eds.).
94. Gao N., Zhang J., Rao M.A., et al. The role of hepatocyte nuclear factor-3&;α (Forkhead Box A1) and androgen receptor in transcriptional regulation of prostatic genes. Mol Endocrinol 2003, 17: 1484-1507.
95. Gao N., Ishii K., Mirosevich J., et al. Forkhead box A1 regulates prostate ductal morphogenesis and promotes epithelial cell maturation. Development 2005, 132: 3431-3443.
96. Mirosevich J., Gao N., Gupta A., et al. Expression and role of FoxA proteins in prostate cancer. The Prostate 2006, 66: 1013-1028.
97. Thomas J.C., Oottamasathien S., Makari J.H., et al. Temporal-spatial protein expression in bladder tissue derived from embryonic stem cells. J Urol 2008, 180: 1784-1789.
98. DeGraff DJ, Clark PE, Cates JM, et al. Loss of urothelial differentiation marker FoxA1 is associated with high grade, late stage bladder cancer and presence of squamous cell carcinoma; (under review).
99. Knowles M.A. Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese?. Carcinogenesis 2006, 27: 361-373.
100. Lin T., Chao C., Saito S., et al. p53 Induces differentiation of mouse embryonic stem cells by suppressing Nanog expression. Nat Cell Biol 2005, 7: 165-171.
101. Gao J., Huang H.Y., Pak J., et al. p53 Deficiency provokes urothelial proliferation and synergizes with activated Ha-ras in promoting urothelial tumorigenesis. Oncogene 2004, 23: 687-696.
102. Yang A., Schweitzer R., Sun D., et al. p63 Is essential for regenerative proliferation in limb, craniofacial, and epithelial development. Nature 1999, 398: 714-718.
103. Mills A.A., Zheng B., Wang X.J., et al. p63 Is a p53 homologue required for limb and epidermal morphogenesis. Nature 1999, 398: 708-713.
104. Cheng W., Jacobs W.B., Zhang J.J., et al. δNp63 plays an anti-apoptotic role in ventral bladder development. Development 2006, 133: 4783-4792.
105. Lopardo T., Lo Iacono N., Marinari B., et al. Claudin-1 is a p63 target gene with a crucial role in epithelial development. PLoS One 2008, 3: e2715.
106. Kim S., Lee J.J., Heo D.S. PPARγ ligands induce growth inhibition and apoptosis through p63 and p73 in human ovarian cancer cells. Biochem Biophys Res Commun 2011, 406: 389-395.
107. Park B.J., Lee S.J., Kim J.I., et al. Frequent alteration of p63 expression in human primary bladder carcinomas. Cancer Res 2000, 60: 3370-3374.
108. Koga F., Kawakami S., Fujii Y., et al. Impaired p63 expression associates with poor prognosis and uroplakin III expression in invasive urothelial carcinoma of the bladder. Clin Cancer Res 2003, 9: 5501-5507.
109. Puig P., Capodieci P., Drobnjak M., et al. p73 Expression in human normal and tumor tissues: Loss of p73α expression is associated with tumor progression in bladder cancer. Clin Cancer Res 2003, 9: 5642-5651.
110. Yokomizo A., Mai M., Tindall D.J., et al. Overexpression of the wild type p73 gene in human bladder cancer. Oncogene 1999, 18: 1629-1633.
111. Smith S.C., Baras A.S., Dancik G., et al. A 20-gene model for molecular nodal staging of bladder cancer: Development and prospective assessment. Lancet Oncol 2011, 12: 137-143.